Rocket Pharmaceuticals Inc

RCKT is in a Stage 2 advance after clearing the 3.55 resistance on strong volume. Price is now extended above rising EMAs with extreme overbought readings on RSI and Options Score. While the medium-term trend remains bullish following the Momentum Breakout, timing is unfavorable until a pullback into the 9/21 EMA zone and prior breakout level near 3.55 offers cleaner entry.

• ↑Anticipated resumption of Danon disease trial after FDA alignment
• ↑Low-dose cohort showed NYHA class improvements, advancing to Phase 2
• ↓Negative earnings yield and poor profitability raise operational sustainability concerns